Gain-of-function mutations in LRRK2, which encodes the leucine-rich repeat kinase 2
(LRRK2), are the most common genetic cause of late-onset Parkinson's disease. LRRK2 is …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial
Parkinson's disease (PD) and a risk factor for the sporadic form. Increased kinase activity …

LRRK2 is one of the most promising drug targets for Parkinson's disease. Though type I
kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors …

Mutations of the human leucine-rich repeat kinase 2 (LRRK2) have been associated with
both, idiopathic and familial Parkinson's disease (PD). Most of these pathogenic mutations …

Citrullination is a post-translational modification catalysed by peptidyl arginine deiminase
(PAD) enzymes, and dysregulation of protein citrullination is involved in various pathological …

1-Methylcyclopropyl aryl ethers (McPAEs) can be viewed as cyclized derivatives of their O-
tert-butyl counterparts. Although these compounds can find use in medicinal chemistry, they …

LRR-kinase 2 (LRRK2) is a multi-domain protein with three catalytically inert N-terminal
domains (NtDs) and four C-terminal domains, including a kinase and a GTPase domain …

More than 40 mutations in the multidomain leucine-rich repeat kinase 2 (LRRK2) are found
and mutation G2019S in the kinase domain is the most concerned with Parkinson's disease …

Understanding the selectivity mechanisms of inhibitors toward highly similar proteins is very
important in new drug discovery. Developing highly selective targeting of leucine-rich repeat …

Leucine-rich repeat kinase 2 (LRRK2) remains a viable target for drug development since
the discovery of the association of its mutations with Parkinson's disease (PD). G2019S (in …